Mitsubishi Tanabe Pharmaceuticals To Merge Two Subsidiaries
This article was originally published in PharmAsia News
Mitsubishi Tanabe Pharmaceuticals announced July 8 that its two wholly owned subsidiaries, Osaka-based MP Technopharma and Yamaguchi-based Tanabe Yamaguchi Seiyaku will merge, effective October 1. The move aims to strengthen production functions and boost efficiency as a group. (Click here for more - Japanese language)
You may also be interested in...
Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.
As draft guidance receives OMB review, FDA’s determination of no economic significance reflects its official position that the thousands of supplements, food and personal care products containing CBDs available in the US are unlawful.
AdvaMed Accell executive director Ashley Wittorf spoke in support of a proposed US House bill that would give financial help to small companies making products to address COVID-19.